0000820608 false 0000820608 2022-08-22 2022-08-22 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): August 22, 2022

 

Commission File Number 000-17119

 

QUANTRX BIOMEDICAL CORPORATION

(Exact name of registrant as specified in its charter.)

 

Nevada   33-0202574

(State or other jurisdiction of

incorporation or organization)

  

(IRS Employer

Identification No.)

 

10190 SW 90th Avenue, Tualatin, Oregon 97123

(Address of principal executive offices)

 

(212) 980-2235

(Registrant’s Telephone number)

 

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of exchange on which registered
N/A   N/A   N/A

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR 240.12b-2)

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

Effective August 22, 2022, Michael Abrams resigned from his position as a member of the Board of Directors of QuantRx Biomedical Corporation (the “Company”). Mr. Abram’s resignation from the Board of Directors is not due to any disagreement with respect to the Company’s operations, policies, or practices.

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

QuantrRx Biomedical Corporation

     
August 23, 2022 By: /s/ Shalom Hirshman
    Shalom Hirschman
    Chief Executive Officer

 

 

QuantRx Biomedical (CE) (USOTC:QTXB)
Historical Stock Chart
From Jan 2025 to Feb 2025 Click Here for more QuantRx Biomedical (CE) Charts.
QuantRx Biomedical (CE) (USOTC:QTXB)
Historical Stock Chart
From Feb 2024 to Feb 2025 Click Here for more QuantRx Biomedical (CE) Charts.